A multi-center, un-controlled, open-labeled trial of the long-term safety of Velmanase Alfa aftercare treatment of subjects with alpha-Mannosidosis whom previously participated in Velmanase Alfa - trials
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Adverse reactions
- Sponsors Chiesi Farmaceutici SpA; Zymenex A/S
- 21 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.
- 21 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.
- 01 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.